Merus (NASDAQ:MRUS) Coverage Initiated by Analysts at HC Wainwright

Share on StockTwits

HC Wainwright began coverage on shares of Merus (NASDAQ:MRUS) in a research note published on Friday, BenzingaRatingsTable reports. The firm issued a buy rating and a $23.00 price target on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Guggenheim dropped their target price on shares of Merus from $26.00 to $23.00 and set a buy rating for the company in a research report on Monday, May 18th. BidaskClub upgraded shares of Merus from a hold rating to a buy rating in a research report on Saturday, June 6th. ValuEngine raised Merus from a hold rating to a buy rating in a research note on Thursday, April 2nd. Royal Bank of Canada lowered Merus from an outperform rating to a sector perform rating and dropped their price target for the stock from $21.00 to $16.00 in a research note on Wednesday, May 27th. Finally, Zacks Investment Research upgraded Merus from a hold rating to a buy rating and set a $14.00 price objective on the stock in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $19.00.

Merus stock opened at $14.80 on Friday. The stock has a market cap of $437.05 million, a price-to-earnings ratio of -5.56 and a beta of 0.75. The business has a 50-day simple moving average of $15.16 and a 200 day simple moving average of $15.31. Merus has a 52 week low of $10.19 and a 52 week high of $20.95.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.14). Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%. The business had revenue of $6.30 million for the quarter, compared to the consensus estimate of $8.05 million. Equities research analysts predict that Merus will post -2.31 EPS for the current year.

In related news, major shareholder Bvf Partners L. P/Il bought 1,462,510 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average cost of $14.00 per share, for a total transaction of $20,475,140.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Bvf Partners L. P/Il purchased 87,254 shares of Merus stock in a transaction that occurred on Monday, June 8th. The shares were bought at an average price of $15.20 per share, for a total transaction of $1,326,260.80. The disclosure for this purchase can be found here. 7.40% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of MRUS. Global Retirement Partners LLC increased its stake in shares of Merus by 62.7% in the first quarter. Global Retirement Partners LLC now owns 2,603 shares of the biotechnology company’s stock worth $31,000 after buying an additional 1,003 shares during the period. California Public Employees Retirement System grew its holdings in Merus by 14.4% in the 4th quarter. California Public Employees Retirement System now owns 11,441 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 1,441 shares during the last quarter. UBS Group AG purchased a new position in shares of Merus in the fourth quarter valued at about $30,000. Marshall Wace North America L.P. purchased a new position in shares of Merus in the fourth quarter valued at about $34,000. Finally, Acadian Asset Management LLC raised its stake in shares of Merus by 29.5% during the fourth quarter. Acadian Asset Management LLC now owns 12,035 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,740 shares during the last quarter. Hedge funds and other institutional investors own 62.02% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Further Reading: S&P 500 Index

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.